Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa

Clin Infect Dis. 2020 Oct 23;71(7):1799-1801. doi: 10.1093/cid/ciaa003.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aminoglycosides
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / drug therapy
  • Cephalosporins / therapeutic use
  • Cross Infection* / drug therapy
  • Healthcare-Associated Pneumonia*
  • Humans
  • Pharmaceutical Preparations*
  • Polymyxins
  • Pseudomonas aeruginosa
  • Tazobactam / therapeutic use
  • Treatment Outcome

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Cephalosporins
  • Pharmaceutical Preparations
  • Polymyxins
  • ceftolozane
  • Tazobactam